
Japan bond yields hit multi-decade highs as fiscal fears mount ahead of election
Yields on the 10-year instrument climbed to 1.599%, the highest since 2008, data from LSEG showed. Yields on the 30-year JGB also rose to a record high of 3.21%, while Japan's 20-year government bond yields spiked to their highest level since 1999.
"Japan's long yields and super-long yields are currently rising due to expectations of fiscal expansion after the Upper House election coming up next week," said Ken Matsumoto, Japan macro strategist at Credit Agricole CIB.
A sizable number of Japanese politicians and parties are actively discussing consumption tax cuts ahead of the upper house election set to take place Sunday.
Japan Prime Minister Shigeru Ishiba has maintained that he will not resort to tax cuts funded by more debt issuance, although opposition parties are calling for tax cuts and more spending, which could lead to more debt.
This political uncertainty is creating doubt over whether Japan's government will stick to fiscal discipline, said Vishnu Varathan, Mizuho Securities' head of macro research for Asia ex-Japan.
Japan has one of the world's highest levels of public debt relative to the size of its economy. While the government has flagged the need for more fiscal discipline, it relies heavily on issuing new debt to fund its obligations. Tax revenues alone are insufficient to cover the government's expenses.
"The most recent trigger is the election. People are concerned about the election because the politicians are talking about consumption tax cuts, and tax cuts of any sort in Japan is suicidal," said Amir Anvarzadeh, Japan equity market strategist at Asymmetric Advisors, who added that tax cuts would be dire given the fiscal situation that Japan is facing.
"This is why the bond vigilantes are out. And they're saying: we need more yield to invest in the bond market. So there's a shorting [going on] in the JGB market," he told CNBC.
Aside from the upcoming election, there are underlying factors at play that could bring forward the Bank of Japan's next rate hike. While still at elevated levels, Tokyo's inflation eased to 3.1% year on year in June, slower than the 3.6% in May.
"This could prompt the BOJ to revise its inflation forecast upward, potentially accelerating the timeline for its next rate hike," said Carlos Casanova, senior economist for Asia at Union Bancaire Privée.
On top of that, supply-demand imbalances in the Japanese bond markets could become more pronounced, especially as life insurers have less capacity to absorb additional supply, said Masahiko Loo, senior fixed income strategist at State Street Investment Management.
In June, the Bank of Japan said it would slow the pace of its government bond purchase reductions starting April next year, and kept its benchmark interest rate steady at 0.5% as economic risks mount. The BOJ reiterated plans to trim its monthly Japanese government bond purchases by roughly 400 billion yen ($2.76 billion) each quarter to about 3 trillion yen till March 2026, in line with guidance set last year.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions
Former FDA Director David Feigal joins Keyron as Head of Regulatory Affairs Dr Joyce Peetermans (ex-Boston Scientific) joins as Acting CTO Christopher Rowland (ex-Boston Scientific) appointed Chairman ForePass aims to replicate metabolic surgery without incisions Preparing for First-In-Human trials after strong large-animal data Head-to-head data showing superiority over $28B/year drug to be published soon LONDON & BOSTON, August 06, 2025--(BUSINESS WIRE)--Keyron, a pioneer in medical devices for advanced metabolic disease, today announced the appointment of three world-class leaders to its board of directors—including the former Director of the FDA's Center for Devices and Radiological Health (CDRH) and senior medtech industry leaders with key roles in notable exits within the endoscopy medical device sector. These appointments strengthen Keyron's regulatory, clinical, and strategic leadership as the company prepares for its upcoming clinical trials, associated global regulatory submissions, and future strategic alliances, centered around its ForePass device. ForePass is designed to replicate the outcomes of metabolic surgery—without cutting, puncturing, or trauma—through a fully reversible, minimally invasive procedure. Board Appointments David Feigal MD (Head of Regulatory Affairs) – Former Director of the FDA's Center for Devices and Radiological Health (CDRH). Covered the highest role and authority in medical devices at the FDA. Brings decades of experience guiding breakthrough technologies through FDA approval and will now be the Company's lead for FDA engagement and IDE submission. Founder of leading U.S. regulatory consultancy, NDA Partners. Widely recognized as one of the most experienced regulatory experts in the U.S., he has held senior global roles at public companies Amgen and Elan and led or advised over 20 successful medical product approvals across therapeutic areas. Joyce Peetermans, Ph.D. (Acting CTO) – 35+ years of leadership roles in R&D, Clinical Research, and Innovation in Gastroenterological and Surgical Endoscopy, and other specialties. She spent 25 years at Boston Scientific, where she was on the Endoscopy Management Board as VP of Global Clinical Programs, and VP of Innovation and Research during the $615M acquisition of Apollo Endosurgery and several other key acquisitions by Boston Scientific Endoscopy. Christopher Rowland (Chairman) – A seasoned executive with over 35 years leading Class III endoscopic and metabolic device companies. He served as President at Given Imaging prior to its $860M PillCam exit to Covidien (Medtronic) and was CEO of Neotract before its $1.1B acquisition by Teleflex. He also spent 17 years in senior roles at Boston Scientific. Christopher will chair Keyron's board of directors and support its corporate development and fundraising strategy. This leadership expansion follows several successful large-animal studies of ForePass demonstrating excellent safety, tolerability, and strong efficacy on both weight and insulin production. Key results were published in Gut (Angelini G, Galvao Neto M, Boskoski I, et al., 2024), showing ForePass's ability to replicate surgery-like results without incisions. The company is now preparing to unveil best-in-class preclinical data showing clear superiority over Semaglutide—the $28B/year standard of care for obesity and diabetes in Ozempic and Wegovy—across all major endpoints. These data are expected to be published this summer. 92% of Semaglutide patients fail to achieve 15% total body weight loss (New England Journal of Medicine, 2021; 385(6):503–515), with 85% discontinuing GLP-1 therapy within just 24 months (Reuters, 10 July 2024). Yet patients with severe obesity (BMI ≥35)—especially those who also have type 2 diabetes—need around 30% weight loss. Since GLP-1s fall substantially short and most stop taking them, surgery remains the only viable option, regularly delivering over 30% weight loss despite its risks and complications. ForePass is a fully removable, endoscopically implantable device aiming to replicate the metabolic benefits of surgery without incisions. It targets patients with BMI ≥35 and diabetes or BMI ≥40—a large, high-risk population underserved by current treatments. Giorgio Castagneto Gissey, Founder & CEO of Keyron, said: "Christopher, David, and Joyce are absolute world-class leaders. Their decision to join Keyron reflects the urgency of the metabolic crisis—especially the unmet need in diabetes and higher BMI—and the unique power of what we've built. Their expertise will be transformative as we enter human trials and deliver the first truly effective, scalable alternative to surgery for millions." Keyron, a VC-backed startup, has developed a proprietary biometabolic implant and endoscopic delivery system, secured leading clinical sites in the U.S. and internationally, and completed long-term preclinical validation. Full efficacy results—including head-to-head data versus Semaglutide in a porcine model—will be published shortly. The company is now preparing for its First-In-Human study. About Keyron Keyron is the first biometabolic device platform company, pioneering a new class of implantable therapies that aim to replicate the effects of bariatric and metabolic surgery without incisions—and restore metabolic health at its root without driving insulin overproduction or dependency. Headquartered in London and Boston, Keyron's mission is to deliver a scalable alternative to surgery—and a better option for patients with severe obesity and diabetes. See for more information. View source version on Contacts Media Contact Keyron Press Officepress@ London, UK and Boston, MA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Registering to vote in East Baton Rouge Parish before 2025 fall elections: What to know
BATON ROUGE, La. (Louisiana First) — With fall elections coming up, East Baton Rouge Parish Registrar of Voters Steve Raborn is asking residents to check their voter registration. The Registrar's Office will host a series of voter registration events across the parish during Louisiana Voter Registration Week, from Aug. 25 through Aug. 29, to make it easier for people to register near their homes or work. Residents can register or update their information online. They can also do this in person at the Registrar of Voters' Office or at library branch voter drives. The drives are from 1 p.m. to 6 p.m. on the dates below: Aug. 25: Bluebonnet Regional, Scotlandville, and Central branch libraries Aug. 26: Carver, Delmont Gardens, and Zachary branch libraries Aug. 27: River Center, Fairwood, and Main libraries Aug. 28: Pride-Chaneyville, Eden Park, and Jones Creek Regional libraries Aug. 29: Greenwell Springs Road Regional, Baker, and South branch libraries To register in person, valid identification that proves identity, age, and residency is required. A Louisiana driver's license is preferred. However, other documents are also accepted, such as a birth certificate, utility bill, payroll check, or any government-issued document that shows your name and address. Council to discuss resolution to remove West Ascension Hospital Board member Deadline to register in person or by mail: Sept. 10. Deadline to register online at Sept. 20. Early Voting: Sept. 27 – Oct. 4. Election Day: Oct. 11. For more information or to check your registration status, visit Latest News See the LSU men's basketball SEC schedule for 2026 Registering to vote in East Baton Rouge Parish before 2025 fall elections: What to know MLB is calling up its first female umpire, Jen Pawol Ex-Trump surgeon general: RFK Jr. vaccine move 'going to cost lives' Chikungunya virus in China: What to know Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
33 minutes ago
- Yahoo
Bakkt Expands Global Bitcoin Play With 30% Stake in Japan's Marusho Hotta
Amid a sea of new crypto treasury companies popping up, Bakkt and BitBridge are in the news today, after they both provided updates on their bitcoin treasury strategies. Bakkt (BKKT), the technology firm that went all-in on crypto, has signed a deal to acquire nearly one-third of Japanese trading company Marusho Hotta (8105), in a move that could signal a broader international bitcoin (BTC) strategy for the U.S.-based digital asset platform, the company said in a press release Wednesday. Under the agreement with RIZAP Group Inc., Bakkt will acquire roughly 30% of the Tokyo-listed company, positioning itself as Marusho Hotta's largest shareholder. Pending shareholder approval, Marusho Hotta will be renamed aligning its brand with its new bitcoin-centric direction, the company said. Bakkt has also secured the domain as part of the deal. In a strategic leadership shift, Phillip Lord, President of Bakkt International, will take over as CEO of Marusho Hotta. Meanwhile, bitcoin treasury firm BitBridge Capital Strategies has completed its merger with Green Mountain Merger Inc., the company said in a press release yesterday. The company will start trading under the ticker symbol BTTL on the over-the-counter (OTC) markets by the end of the third quarter, with plans to uplist to NASDAQ thereafter.